Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 267 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Taking of blood samples Clear all
Recruiting Not applicable Interventional

Changes in Body Composition Including Muscle With Anti-Obesity Medications, Both With and Without Exercise

NCT07698145
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Standard Medical Care with an Obesity Management Medication, Cardiovascular Exercise Training, Resistance Exercise Training, Nutrition Counseling
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Withdrawn No phase listed Observational

Effects of Swallowed Steroids on Bone Density and Growth in Pediatric Eosinophilic Esophagitis

NCT03615950
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Bone Mineral Density (DEXA) scan, Vitamin D Measurement, Height measurement, Assessment of medication compliance
Diagnostic Test · Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
5 Years to 12 Years
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 2, 2026, 2:22 AM EDT
Terminated Phase 1 Interventional

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

NCT01585415
View directory record Official record
Conditions
Metastatic Cancer, Melanoma
Interventions
Vemurafenib, Young TIL, Cyclophosphamide, Fludarabine, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 2, 2026, 2:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

NCT06485089
View directory record Official record
Conditions
Obesity, Breast Cancer Risk
Interventions
tirzepatide
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Kansas City, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

A Study for Leukemia Patients With Life-Threatening Infections

NCT00968838
View directory record Official record
Conditions
Leukemia
Interventions
White Blood Cell Transfusion
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

NCT01035229
View directory record Official record
Conditions
Carcinoma
Interventions
Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 2, 2026, 2:22 AM EDT
Recruiting No phase listed Observational

Assessment of Methadone Dose Taken

NCT05981573
View directory record Official record
Conditions
Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
Interventions
Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
Diagnostic Test · Drug · Device
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 3 Interventional

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

NCT01336751
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Oct 2, 2026, 2:22 AM EDT
Completed No phase listed Observational

Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate

NCT00341029
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Years to 12 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 2:22 AM EDT
Completed No phase listed Observational

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

NCT04301661
View directory record Official record
Conditions
HIV-1-infection
Interventions
Blood collection, Abacavir/lamivudine, Tenofovir alafenamide/emtricitabine, Switch
Other · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 2, 2026, 2:22 AM EDT
Enrolling by invitation No phase listed Observational

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments

NCT05371483
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
24-hour Ambulatory Blood Pressure Monitoring, Oculo-Cognitive Addition Test (OCAT)
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 1 Interventional Results available

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

NCT01758731
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Olaparib, Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 2, 2026, 2:22 AM EDT
Completed No phase listed Observational Results available

Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey

NCT04317690
View directory record Official record
Conditions
High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 2, 2026, 2:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen

NCT05056857
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Terminated No phase listed Observational

The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study

NCT02735720
View directory record Official record
Conditions
Thoracic Aortic Aneurysm
Interventions
TEVAR, Non-TEVAR medical treatment
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 2, 2026, 2:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Adenosine 2A Receptor Antagonism and AIH in ALS

NCT05377424
View directory record Official record
Conditions
ALS
Interventions
Consume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug, SHAM counterpart to low oxygen therapy.
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524
View directory record Official record
Conditions
Von Willebrand Disease, Type 3
Interventions
Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Month and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure

NCT00624559
View directory record Official record
Conditions
Hypertension
Interventions
celecoxib (Celebrex), Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
22 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 2, 2026, 2:22 AM EDT
Active, not recruiting Not applicable Interventional

Probiotics for Inflammation in Pediatric Chronic Pain

NCT05141890
View directory record Official record
Conditions
Chronic Pain, Body Mass Index >=85th Percentile
Interventions
Lactobacillus Plantarum
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
13 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 2:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Tysabri
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 2, 2026, 2:22 AM EDT
Completed Not applicable Interventional Results available

Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

NCT01987830
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
MRI-PET, TMZ-PET
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 2, 2026, 2:22 AM EDT
Withdrawn Phase 2 Interventional

Autologous Transplant Targeted Against Crohn's

NCT04154735
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fludarabine, Cyclophosphamide, Mesna, Alemtuzumab, G-CSF, Rifaximin, Tacrolimus
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 49 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 2, 2026, 2:22 AM EDT
Not yet recruiting Not applicable Interventional

Menstruation and Anemia Research: A Community Health Study

NCT07832526
View directory record Official record
Conditions
Anemia
Interventions
Standard of Care, Informational Series and follow-up support
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 55 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 2:22 AM EDT